Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences

Company Overview - Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for endocrine diseases and endocrine-related tumors [4] - The company's lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist, currently in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors [4] - Crinetics is also developing atumelnant, an investigational first-in-class oral ACTH antagonist for the treatment of congenital adrenal hyperplasia and Cushing's disease [4] - All drug candidates are orally delivered, small molecules resulting from in-house drug discovery efforts, addressing various endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, diabetes, obesity, and GPCR-targeted oncology indications [4] Upcoming Events - Company management will participate in the TD Cowen 45th Annual Healthcare Conference in Boston, MA, on March 3, 2025, at 11:10 a.m. Eastern Time [2] - Management will also participate in the Leerink Global Healthcare Conference in Miami, FL, on March 10, 2025, at 4:20 p.m. Eastern Time [2] - Live and archived webcasts of these events will be accessible on the Events & Presentations page of the Crinetics website [2]